Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, affecting up to nearly 38% of the adult population [1]. MASLD is strongly associated with type 2 diabetes (T2D) and obesity, with nearly 65%–70% of patients with T2D showing MASLD.

MASLD and metabolic dysfunction‐associated steatohepatitis (MASH), the histologic phenotype of MASLD characterised by liver injury and inflammation in addition to steatosis, is a major public health issue as it increases the risk of liver‐related complications, such as cirrhosis and hepatocellular carcinoma, while also increasing the rates of fatal and nonfatal cardiovascular events, chronic kidney disease, T2D, extrahepatic cancers [1] and severe bacterial and non‐bacterial infections [2]. Treatment for MASLD usually involves lifestyle modifications aimed at preventing cardiovascular complications, avoiding further liver damage, potentially improving fibrosis stage and, ultimately, reducing liver‐related mortality [3]. These interventions include, among others, the switch to a Mediterranean hypocaloric diet, reduced alcohol consumption and increased physical exercise [3, 4]. When focussing on liver‐related complications, the achievement of a weight loss of at least 5% is the main aim, as it is associated with improvements in liver steatosis, inflammation and fibrosis [3]. This endpoint is complex because it is difficult to achieve in clinical practice, and long‐term adherence to lifestyle interventions is questionable [5]. For these reasons, the development of effective treatments for MASLD that improve survival by reducing both hepatic and extrahepatic complications is a significant and partly unmet clinical need. The first major breakthrough in the field was the 2024 US Food and Drug Administration (FDA) conditional approval of resmetirom, an orally administered, liver‐targeted thyroid hormone receptor (THR)‐β selective drug [6]. Resmetirom, which was also approved in August 2025 by the European Medicines Agency (EMA), is indicated for the treatment of adults with non‐cirrhotic MASH with moderate to advanced fibrosis and has been administered to over 23 000 patients in the USA (https://ir.madrigalpharma.com/news‐releases/news‐release‐details/madrigal‐pharma‐reports‐second‐quarter‐2025‐financial↗). On August 15th, 2025, the FDA granted an accelerated and conditional approval of the subcutaneous glucagon‐like peptide (GLP‐1) receptor agonist (GLP1‐RA) semaglutide 2.4 mg/week for the treatment of MASH with moderate to advanced fibrosis (Stage F2‐F3) [7]. This represents a new indication for semaglutide, which is also approved for the treatment of T2D, prevention of cardiovascular events in people with obesity and treatment of obesity/overweight associated with metabolic disorders. The availability of semaglutide and resmetirom for the treatment of patients with MASLD/MASH with moderate and advanced fibrosis offers physicians two therapeutic options that differ in terms of mechanisms of action, safety and tolerability.

In this review article, we will focus on subcutaneous semaglutide 2.4 mg/week by analysing available efficacy and safety data to offer practical recommendations for its clinical use in people with MASLD.

Data from the ongoing phase 3, multicentre, placebo‐controlled ESSENCE trial involving patients with biopsy‐confirmed MASH and liver fibrosis (stage F2 or F3) demonstrated that subcutaneous semaglutide 2.4 mg/week not only improves steatosis but also reduces necroinflammation, hepatocellular ballooning and fibrosis [8].

The most robust explanation for the hepatoprotective effects of semaglutide in improving and/or potentially reversing liver histological outcomes, including hepatic fat accumulation, is linked to the so‐called indirect effects of the drug. In this context, it has been proposed that semaglutide and other GLP1‐RA modulate insulin signaling pathways, thereby increasing hepatic insulin sensitivity, improving glucose uptake and utilisation and reducing hepatic gluconeogenesis [9]. Semaglutide also exerts its action on steatosis through several indirect mechanisms that contribute to substantial weight loss, including effects on caloric intake, which involve interference with central appetite suppression and satiety. Moreover, the drug reduces blood lipid levels while concomitantly modulating systemic inflammatory processes [9]. Consequently, semaglutide may beneficially affect liver steatosis by interfering with metabolic cascades and molecular pathways, including fatty acid synthesis and fatty acid β‐oxidation, which may in turn prevent the accumulation of lipid droplets in hepatocytes [9, 10, 11].

While the systemic biological effects of semaglutide that indirectly benefit MASLD/MASH are robustly validated, a knowledge gap persists concerning the drug's direct effects on the liver, alongside the scientific controversy surrounding the gene and protein expression of GLP‐1 receptor (GLP‐1R) in the liver [12]. Indeed, while several studies failed to detect GLP‐1R mRNA in the human or rodent liver [13, 14], it is conceivable that GLP‐1R might be expressed in non‐hepatic cells, such as immune cells or intrahepatic blood vessels [12]. Gupta et al. hypothesised a possible mechanism of action of GLP1‐RAs by demonstrating a protective effect on hepatocytes against death related to free fatty acids (FFAs). This would be theoretically achieved by inhibiting a dysfunctional endoplasmic reticulum stress response and reducing fatty acid accumulation through the activation of both macroautophagy and chaperone‐mediated autophagy [15]. However, it is essential to exercise caution when interpreting these results, as the study was based on the assumption that exendin‐4/GLP‐1—but not semaglutide—binds to a cognate receptor on human hepatocytes.

Therefore, is it reasonable to consider whether semaglutide directly affects liver fat or liver inflammation when GLP‐1R is not present in the liver? GLP‐1R is a 7‐transmembrane protein that functions as a receptor for the GLP‐1 hormone. The protein predominantly localises to the cellular membranes of diverse cell types throughout the human body. The most prominent molecular functions and biological processes annotated with GLP‐1R (https://functionome.geneontology.org/gene/UniProtKB:P43220↗) are peptide hormone binding, GLP‐1R activity, adenylate cyclase‐modulating G protein‐coupled receptor signalling pathway and positive regulation of blood pressure. This is a particularly interesting phenomenon, given that GLP‐1R is a member of the class B family of peptide hormone G protein–coupled receptors (GPCRs). When a GLP‐1RA, including semaglutide, is administered, it triggers the activation of G‐proteins, leading to an increase in the intracellular second messenger cAMP [9]. Furthermore, GLP‐1Rs, like numerous other transmembrane proteins, may initiate signalling through interactions with other proteins on the liver cell's surface or within the cell, thereby triggering a sequence of events that result in diverse cellular response processes. Besides, semaglutide might act by modifying systemic proteostasis, thereby affecting the balance between various proteins within the intrahepatic pathways of MASH. A recent study explored the circulating proteome associated with MASH in patients treated with semaglutide, identifying a ‘treatment signature’ comprising 72 unique proteins that were significantly associated with the drug dosage and MASH resolution [13]. In summary, it is evident that a considerable proportion of the pleiotropic benefits of semaglutide, including its liver‐related effects, could be attributable to still unidentified signalling pathway(s), which may be distinct from the canonical GLP‐1R activation.

The clinical development of semaglutide for patients with MASH has progressed through comprehensive phase 2 and phase 3 trials, providing robust evidence across primary histological outcomes, secondary histological endpoints, non‐invasive biomarkers and metabolic parameters.

The initial phase 2 trial established the foundation for semaglutide's efficacy in MASH, enrolling 320 patients with biopsy‐confirmed NASH, the previous nomenclature for MASH and fibrosis stages F1–F3 [32]. In this 48‐week study, patients receiving subcutaneous semaglutide 0.4 mg daily achieved MASH resolution without worsening of fibrosis in 59% of cases compared to 17% in the placebo group, which was highly significant. However, improvement in fibrosis stage occurred in 43% of patients in the 0.4‐mg group versus 33% in the placebo group, failing to reach statistical significance. The mean percent weight loss was 13% in the 0.4‐mg group compared to 1% in the placebo group, demonstrating semaglutide's metabolic benefits alongside histological improvements [32].

The ESSENCE phase 3 trial represents the most substantial evidence for semaglutide's efficacy in MASH, enrolling 800 patients with biopsy‐confirmed MASH and fibrosis stage 2 or 3 [8]. Table 1 presents data on the efficacy and safety of semaglutide from the ESSENCE trial. The study demonstrated compelling results for both co‐primary endpoints at 72 weeks. Resolution of steatohepatitis without worsening of liver fibrosis was achieved in 62.9% of patients receiving semaglutide 2.4 mg weekly, compared to 34.3% in the placebo group (estimated difference, 28.7 percentage points; 95% CI, 21.1–36.2). Importantly, the phase 3 trial also demonstrated significant efficacy for the second primary endpoint: reduction in liver fibrosis without worsening of steatohepatitis occurred in 36.8% of semaglutide‐treated patients versus 22.4% of placebo recipients (estimated difference 14.4 percentage points; 95% CI 7.5–21.3). This represented a significant advancement from the phase 2 results, likely attributable to the higher dose (2.4 mg weekly vs. 0.4 mg daily), longer treatment duration and optimised study design.

The ESSENCE trial revealed additional histological benefits beyond the primary endpoints. Combined resolution of steatohepatitis and reduction in liver fibrosis occurred in 32.7% of semaglutide patients versus 16.1% of placebo patients (estimated difference 16.5 percentage points; 95% CI 10.2–22.8). Analysis of individual histological components showed that more patients receiving semaglutide experienced reductions in steatosis, ballooning and total NAS. Notably, among patients with F2 fibrosis at baseline, only 8.7% of patients treated with semaglutide progressed to F3, compared to 20% of patients treated with placebo. Additionally, improvement in fibrosis stage of ≥ 1 stage was more common with semaglutide treatment (44.6% vs. 28.6% in the placebo group). These findings build upon the phase 2 results and demonstrate the enhanced efficacy achieved with the optimised dosing regimen.

Semaglutide demonstrated consistent improvements across multiple non‐invasive markers of liver health in the ESSENCE trial. The enhanced liver fibrosis (ELF) score showed favorable changes, with 55.8% of semaglutide patients achieving a clinically meaningful decrease of ≥ 0.5 compared to 25.5% of placebo patients. Liver stiffness measured by vibration‐controlled transient elastography (VCTE) revealed that 52.0% of semaglutide patients achieved ≥ 30% reduction versus 30.3% of placebo recipients. Liver enzymes showed early and sustained improvements, with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels declining significantly by 12 weeks and maintaining improvement throughout the study period. The percentage of patients achieving ALT reduction ≥ 17 IU/L was 52.1% with semaglutide versus 22.2% with placebo. The FibroScan‐AST (FAST) score and plasma N‐terminal propeptide of type III collagen (PRO‐C3) levels also improved with semaglutide treatment, providing objective biomarker evidence to support the histological findings [8].

Weight reduction represents one of semaglutide's most consistent benefits across all studies. In the ESSENCE trial, at week 72, patients achieved a mean weight reduction of 10.5% with semaglutide versus 2.0% with placebo (estimated difference −8.5 percentage points). This was comparable to the 13% weight loss observed in the phase 2 trial with the 0.4 mg daily dose, indicating consistent metabolic efficacy across different dosing regimens. Glycaemic control improved substantially in patients with T2D. In the ESSENCE trial, patients with T2D showed HbA1c reduction of −1.08% with semaglutide versus 0.0% with placebo, while those without T2D showed a reduction of −0.42% versus +0.11% with placebo. Insulin resistance, as estimated by HOMA‐IR, showed greater improvement in patients with T2D compared to those without T2D. Lipid profiles also showed consistent improvements, particularly in circulating levels of triglycerides and very low‐density lipoprotein (VLDL) cholesterol. The ESSENCE trial reported significant reductions in plasma triglycerides (mean absolute change −16.77 mg/dL vs. −0.27 mg/dL with placebo) and improvements in plasma HDL cholesterol (+2.62 mg/dL vs. −1.95 mg/dL). Plasma high‐sensitivity C‐reactive protein levels decreased significantly by 53.8 mg/L with semaglutide versus 19.8 mg/L with placebo, indicating reduced systemic chronic inflammation. Blood pressure also improved, with systolic pressure reducing by 5.4 mmHg with semaglutide versus 1.4 mmHg with placebo.

Semaglutide demonstrated a favourable safety profile consistent with its established use in T2D and obesity across both phase 2 and phase 3 studies. In the ESSENCE trial, 86.3% of patients treated with semaglutide experienced adverse events, compared to 79.7% of patients receiving placebo, with serious adverse events occurring equally in both treatment arms (13.4%). Importantly, only 2.6% of patients treated with semaglutide discontinued treatment due to adverse events, compared to 3.3% in the placebo group. Gastrointestinal disorders represented the most common adverse events, including nausea (36.2% vs. 13.2%), diarrhoea (26.9% vs. 12.2%), constipation (22.2% vs. 8.4%) and vomiting (18.6% vs. 5.6%). These events were typically mild to moderate and transient, occurring primarily during dose escalation. The incidence of acute pancreatitis was similar between groups (0.4% vs. 0.5%). Hypoglycaemia occurred in 7.4% of semaglutide patients with type 2 diabetes versus 5.4% with placebo, with only level 2 or 3 events counted. Target dose maintenance was excellent, with 88.0% of patients maintaining the target dose of 2.4 mg until week 72. Nine patients died during the study (three in the semaglutide group and six in the placebo group), with no evident clustering of cause of death. The safety profile remained consistent with previous semaglutide studies, with no new safety signals identified. However, no data were reported about the impact of semaglutide treatment on muscle mass loss, this finding being worthy of further exploration in a population at high risk of sarcopenic obesity, like MASH patients with fibrosis [34].

The comprehensive clinical evidence from phase 2 and phase 3 trials supports semaglutide as an effective therapy for MASH with fibrosis stages F2–F3, showing significant histological improvements alongside substantial metabolic benefits and an acceptable safety profile.

The efficacy of semaglutide in patients with MASH‐related compensated cirrhosis has formally been assessed only in one phase 2 RCT [33]. In this small trial, 71 patients with biopsy‐proven compensated cirrhosis and BMI ≥ 27 kg/m² (75% with T2D, mean BMI 34.9 kg/m²) were randomised to semaglutide 2.4 mg once weekly (n = 47) or placebo (n = 24) for 48 weeks. Semaglutide conferred the expected metabolic benefits, including significant weight loss, improved glycaemic control and reductions in liver fat and inflammatory markers. Safety was acceptable, with no hepatic decompensation events or deaths reported, and both liver and kidney function remained stable. However, the trial did not meet its primary endpoint. Fibrosis regression without worsening of MASH was observed in 11% of semaglutide‐treated patients compared with 29% in the placebo group (OR 0.28, 95% CI 0.06–1.24; p = 0.09). Similarly, rates of MASH resolution did not differ significantly between the groups. Notably, the lack of supportive signals from non‐invasive fibrosis measures, including magnetic resonance elastography, suggests that the seemingly greater fibrosis improvement in the placebo group may have been affected by biopsy variability and the unmasking effect of reduced steatosis [35].

These results highlight a key concept: while semaglutide improves the metabolic milieu that drives disease progression, it does not seem to reverse established cirrhosis within the studied timeframe. This aligns with the lack of direct GLP‐1 receptor signalling in human hepatocytes [36], possibly leading to an ‘irreversibility threshold’ on the beneficial effect on liver damage once advanced architectural remodelling has occurred. On the other hand, different drug classes, namely fibroblast growth factor receptor‐21 (FGF‐21) analogues, that target directly hepatocytes, but also adipose tissue and the central nervous system, and possibly also hepatic stellate cells [37, 38, 39], have shown a potential to reverse early‐stage cirrhosis [40]. From a clinical perspective, semaglutide in cirrhotic patients should therefore be considered primarily a metabolic intervention. It is useful for controlling weight, glycaemia and cardiovascular risk, but it does not function as an antifibrotic therapy. Two complementary strategies may help to overcome this limitation. First, GLP‐1RAs should be introduced earlier in the disease course, particularly in patients with significant but not yet cirrhotic fibrosis (stages F1–F3), where they have demonstrated the ability to slow progression and induce MASH resolution. Second, combining GLP‐1RAs with liver‐directed therapies, such as resmetirom, might provide synergistic benefits by addressing both the upstream metabolic drivers and the intrahepatic fibrosis processes of MASH [41, 42]. Importantly, although semaglutide appeared safe in this specific patient population, additional larger and longer‐term studies, including also people with more severe liver disease, will be necessary to examine not only the potential benefits, but also the safety of semaglutide in patients with a hypercatabolic state at high risk of sarcopenia, which has a detrimental impact on prognosis [43]. However, the relatively short study duration (only 48 weeks, including the drug titration phase) and the small sample size do not allow for a definitive conclusion regarding the potential efficacy and safety of semaglutide in patients with MASH‐related cirrhosis.

Substantial evidence from large multicentre, placebo‐controlled RCTs has shown that treatment with once‐weekly subcutaneous semaglutide (or other GLP‐1RAs) reduces the risk of adverse cardiovascular and renal outcomes, as well as hospitalisations for heart failure in patients with overweight or obesity, regardless of their T2D status [44].

In a 2021 meta‐analysis of eight large phase 3 cardiovascular outcome RCTs, involving 60 080 patients with T2D, Sattar et al. reported that GLP‐1RAs, regardless of structural homology, reduced the risk of major adverse cardiovascular events (i.e., 3‐point major adverse cardiovascular events (MACE), including nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) by 14% (HR 0.86, 95% CI 0.80–0.93), all‐cause mortality by 12% (HR 0.88, 95% CI 0.82–0.94) and hospital admissions for heart failure by 11% (HR 0.89, 95% CI 0.82–0.98) [45]. In another meta‐analysis of five cardiovascular outcome RCTs, Barkas et al. reported that compared to placebo, GLP‐1RAs significantly reduced the risk of developing ischemic stroke by 13% (HR 0.87; 95% CI 0.78–0.98) [46].

Interestingly, the cardiovascular benefits of GLP‐1RAs do not seem to be limited only to patients with T2D [47, 48]. In the SELECT trial, an event‐driven superiority phase 3 placebo‐controlled RCT that included 17 604 participants with preexisting cardiovascular disease and overweight/obesity but no history of T2D, Lincoff et al. reported that semaglutide 2.4 mg/week was superior to placebo in reducing the risk of 3‐point MACEs over a mean follow‐up of ~3.5 years (HR 0.80; 95% CI 0.72–0.90) [47]. A subgroup analysis of the SELECT trial showed that semaglutide 2.4 mg/week was effective in lowering the risk of MACEs by 21% and 36% in patients with an intermediate and high likelihood of advanced liver fibrosis, as identified by a baseline FIB‐4 index of ≥ 1.3 and ≥ 2.67, respectively. This suggests that the cardiovascular benefits of semaglutide also extend to a patient population with this liver condition [49]. Recently, in a post hoc pooled participant‐level analysis of four placebo‐controlled RCTs, Kosiborod et al. examined the effects of once‐weekly subcutaneous semaglutide (2.4 mg/week in SELECT, STEP‐HFpEF and STEP‐HFpEF DM; 1.0 mg/week in FLOW) on heart failure events. These investigators found that obese patients who had heart failure with preserved ejection fraction, semaglutide significantly reduced the risk of the combined endpoint of cardiovascular death or worsening heart failure events (HR 0.69, 95% CI 0.53–0.89), and worsening heart failure events alone (HR 0.59, 95% CI 0.41–0.82) [50].

Data on the renal benefits of GLP‐1RAs were initially reported from analyses of secondary outcomes in cardiovascular outcome trials, which also measured estimated glomerular filtration rate (eGFR) and albuminuria [44]. In a 2021 meta‐analysis of cardiovascular outcome RCTs published by Sattar et al., GLP‐1RAs significantly reduced the risk of a composite kidney outcome consisting of the development of abnormal albuminuria, doubling of serum creatinine, or at least a 40% decline in eGFR, kidney replacement therapy, or kidney‐related death by 21% (HR 0.79; 95% CI 0.73–0.87) [45]. Recently, the phase 3 placebo‐controlled FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial showed that once‐weekly subcutaneous semaglutide (at a dose of 1.0 mg) for a median of 3.4 years was superior to placebo in reducing the risk of major kidney disease events (HR 0.79; 95% CI 0.66–0.94), i.e., a composite of the onset of kidney failure, at least a 50% reduction in eGFR from baseline, or death from kidney‐related causes, in 3533 patients with T2D and chronic kidney disease [51]. Interestingly, in a subsequent analysis of the same FLOW trial, the investigators also showed that the benefits of semaglutide in improving major kidney outcomes were consistent in participants with or without concomitant use of SGLT2 inhibitors [52].

In real‐world analyses of 7847 Italian individuals with T2D on GLP‐1RAs, women had a 16% higher probability of discontinuation, with no differences in dose escalation or maximum dose [53]. Over more than 5 years of follow‐up, women showed ~1 kg greater weight loss but no difference in HbA1c reduction. Given their higher dropout rate, the population‐level benefit might be attenuated. Theoretically, since body weight is a key determinant of MASLD, even a 1‐kg difference could matter in the long term, but whether this statistically significant difference translates into clinical benefits remains uncertain. A meta‐analysis of RCTs reported no strong predictors of HbA1c response, except for lower baseline insulin production [54]. Ethnicity showed a moderate interaction: people of African or Asian ancestry experienced greater cardiovascular benefit compared to those of European ancestry after GLP‐1RAs agonist treatment [54].

MASLD is highly heritable [55]. Common PNPLA3 and TM6SF2 variants strongly influence onset and interact with excess body weight, amplifying liver injury. GLP‐1RAs may, therefore, have greater benefit in carriers of these variants. This is consistent with data showing larger serum ALT reductions in PNPLA3 p.I148M (rs738409) carriers treated with semaglutide [56]. The impact of GLP‐1RAs on liver‐related events according to the genetic background remains, however, to be clarified.

Recent studies suggest at least two MASLD subtypes: one driven by lipoprotein retention and the other by increased DNL with impaired β‐oxidation [57]. Whether GLP‐1 RAs agonists may have different effects on these mechanistic subtypes remains an open question. Alcohol intake may also influence response, as GLP‐1 RAs agonists reduce alcohol consumption [58], potentially offering dual benefits for liver disease.

Sub‐group analyses from the phase 3 ESSENCE trial also reported that the effects of semaglutide on both MASH resolution and fibrosis improvement remain consistent across age, sex, presence of T2D and BMI categories. However, the difference versus placebo was not significant in patients with BMI < 27 kg/m² for fibrosis improvement. These data should be interpreted with caution due to post hoc analyses on sometimes small subgroups and are therefore worthy of confirmation and further exploration in real‐life studies.

Overall, it is still early to identify predictors of MASLD response to GLP‐1RAs. Future research should consider the genetic background, metabolic subtypes, sex and lifestyle factors to discover reliable predictors, especially for liver‐related events in MASLD people treated with semaglutide.

According to regulatory agencies and the recommendations of scientific societies [3, 42], semaglutide is now an option as a first‐line treatment for people with MASH and fibrosis stage F2–F3, irrespective of the severity of metabolic comorbidities and the presence of obesity and T2D [59]. Thanks to the pleiotropic effects on glucose control and weight loss, and the ability to prevent cardiovascular events in people with severe metabolic dysfunction, the ideal candidates that are most likely to benefit, both concerning hepatic and cardiometabolic outcomes, are patients with severe overweight/obesity and/or T2D [42]. Indeed, it is important to note that in people with MASH and fibrosis stage F2–F3, cardiovascular disease remains the leading cause of morbidity and mortality [60]. However, the benefit of switching to semaglutide in patients who are already on other GLP‐1RA or dual incretin agonists [61] is currently unproven. Combination with resmetirom, which has a different, liver‐directed mechanism of action aimed at reducing hepatic fat, will likely be the more reasonable option for patients on GLP‐1RA with persistent MASH and fibrosis. In our opinion, semaglutide and GLP‐1RA should not be discontinued due to the protective effect on cardiometabolic and renal comorbidities.

Current evidence does not support the prescription of semaglutide to induce liver fibrosis regression in patients with MASLD and cirrhosis [33]. However, semaglutide can be used to treat T2D and obesity, with caution regarding its potential detrimental effects on sarcopenia [43]. Combination with nutritional supplements [62] or physical activity programs [63] may represent an option in this setting.

Finally, one could argue that in the long term, the benefit of semaglutide might be even greater in younger patients at an earlier stage of disease with less severe liver fibrosis, to prevent the progression to significant liver disease, CVD and renal complications. Additional studies are necessary to test this hypothesis and to prove its cost‐effectiveness. Meanwhile, semaglutide can be prescribed to all patients who have other indications, with a high likelihood of reducing liver fat accumulation and the progression to hepatic and extra‐hepatic diseases [64].

Coming back to patients with MASH, the selection of those with F2–F3 fibrosis can be based on non‐invasive criteria, such as fibrosis biomarker panels or, most commonly, increased liver stiffness measurement (LSM) [6, 65]. Evidence consistently demonstrates that LSM below 8 kPa can effectively rule out patients at risk for advanced fibrosis, whereas values at or above 10 kPa can efficiently detect compensated advanced chronic liver disease with increased risk for long‐term liver‐related complications [66]. Furthermore, the predictive capacity of Fibroscan‐derived LSM for liver‐related events equals or exceeds that of histological at‐risk MASH or histological fibrosis assessment [67]. Accordingly, LSM serves as an effective surrogate marker for determining patients who would benefit from semaglutide therapy, with the 10 kPa LSM cutoff likely identifying those requiring the most immediate clinical intervention, while emphasizing the importance of excluding individuals with LSM exceeding 20 kPa or those presenting clinical, imaging, or endoscopic evidence of portal hypertension, circumstances where semaglutide prescription is currently not specifically indicated. The clinical availability of semaglutide raises another critical consideration: establishing how and when to assess treatment response. Clinical trial evidence suggests that histological responders can be identified by a minimum 30% reduction in MRI‐PDFF‐measured hepatic fat content and a decrease of at least 17 IU in serum ALT levels from baseline values at 3 months [68]. Large cohort studies have shown that a reduction of at least 20% in LSM during follow‐up predicts a decrease in the risk of developing long‐term liver‐related events [69]. Additionally, research supports the notion that lifestyle‐based interventions resulting in a weight reduction of at least 5% over one year can produce histological steatosis improvement. In contrast, weight loss of 7%–10% or greater may achieve MASH resolution and reduce fibrosis [70]. Given the substantial impact of semaglutide on weight reduction, this parameter could serve as a response indicator. Proposed evaluation strategies could encompass monitoring weight loss of a minimum of 5%, a serum ALT level decrease and a 20% LSM reduction at 6–12 months intervals. In case of lack of surrogate response or in case of clinical progression, the choice to stop the treatment or add another drug should be based on the liver and metabolic risk profiles of the individual patient. Figure 2 illustrates a possible algorithm for managing semaglutide treatment in clinical practice.

Semaglutide has become a major pharmacologic advance for patients with MASLD/MASH. Robust phase 3 data show that subcutaneous semaglutide (2.4 mg weekly) leads to clinically meaningful and consistent improvements in hepatic steatosis, necroinflammation, fibrosis and resolution of MASH, accompanied by substantial weight loss and positive metabolic effects (better glucose control, lipids and blood pressure), as well as consistent cardiovascular and renal benefits. The safety profile of semaglutide in controlled trials is predictable and manageable, with gastrointestinal effects being the most common adverse events, and no new safety signals have been identified so far.

Evidence that semaglutide benefits patients with established cirrhosis through cirrhosis regression or a reduction in liver‐related complications is modest or inconsistent; therefore, in this clinical setting, semaglutide should, therefore, be regarded primarily as a metabolic disease‐modifying therapy rather than a proven antifibrotic capable of reversing advanced scarring. Uncertainties also persist about the drug's direct hepatic mechanisms (given unresolved questions about intrahepatic GLP‐1 receptor expression), the long‐term durability of histological responses, effects on muscle mass in elderly populations at risk for sarcopenic obesity, and the optimal patient selection strategy in real‐world settings.

In addition, the potential beneficial impact of semaglutide in reducing alcohol intake in people with MASH and harmful consumption [71, 72], especially in those with MetALD, should be evaluated in further studies.

From a practical standpoint, semaglutide is best positioned for patients with active MASH and clinically significant fibrosis (particularly F2–F3 by biopsy or concordant non‐invasive testing), especially those with obesity and/or T2D who stand to gain both hepatic and cardio‐renal benefits. Treatment management decisions should be individualised, with baseline and on‐treatment monitoring using weight, ALT (an early biochemical change), MRI‐PDFF, or a ≥ 30% PDFF change, where available, and longitudinal LSM (targeting a ≥ 20% reduction) guiding clinical decisions.

Further studies are needed to examine the clinical benefit of semaglutide in people with less severe liver fibrosis, as well as its combination with resmetirom or other pharmacological approaches in those with aggressive or treatment‐resistant MASH.

All authors contributed to drafting the manuscript and approved the last version.

L.V. reports speaking fees from: Viatris, Novo Nordisk, GSK; consulting for: Novo Nordisk, Pfizer, Boehringer Ingelheim, Resalis, GSK, ALMAC, AIRNA. S.P. served as a speaker or advisor for Boehringer, Echosens, Madrigal, MSD, Novo Nordisk, Pfizer and Resalis. A.A. served as a speaker or advisor for Madrigal, MSD, Novo Nordisk, AbbVie, Gilead Sciences, Ipsen and BMS. Other authors do not declare any relevant conflict of interest.

Open access publishing facilitated by Universita degli Studi di Milano, as part of the Wiley ‐ CRUI‐CARE agreement.

Petta S., Kim K., Targher G., et al., “Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis,” Liver International 45, no. 11 (2025): e70407, 10.1111/liv.70407.

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.